Preclinical translation of exosomes derived from mesenchymal stem/stromal cells

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Exosomes are nanovesicles secreted by virtually all cells. Exosomes mediate the horizonal transfer of various macromolecules previously believed to be cell-autonomous in nature, including nonsecretory proteins, various classes of RNA, metabolites, and lipid membrane-associated factors. Exosomes derived from mesenchymal stem/stromal cells (MSCs) appear to be particularly beneficial for enhancing recovery in various models of disease. To date, there are over 200 preclinical studies of exosome-based therapies in a number of different animal models. Despite a growing number of studies reporting the therapeutic properties of MSC-derived exosomes, their underlying mechanism of action, pharmacokinetics, and scalable manufacturing remain largely outstanding questions. Here, we review the global trends associated with preclinical development of MSC-derived exosome-based therapies, including immunogenicity, source of exosomes, isolation methods, biodistribution, and disease categories tested to date. Although the in vivo data assessing the therapeutic properties of MSC-exosomes published to date are promising, several outstanding questions remain to be answered that warrant further preclinical investigation.

Original languageEnglish (US)
JournalStem Cells
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Exosomes
Mesenchymal Stromal Cells
Therapeutics
Membrane Lipids
Animal Models
Pharmacokinetics
RNA

Keywords

  • exosomes
  • extracellular vesicles
  • mesenchymal stem cells
  • mesenchymal stromal cells
  • microvesicles

ASJC Scopus subject areas

  • Molecular Medicine
  • Developmental Biology
  • Cell Biology

Cite this

@article{890244b09f1d4180b9f28c2221472885,
title = "Preclinical translation of exosomes derived from mesenchymal stem/stromal cells",
abstract = "Exosomes are nanovesicles secreted by virtually all cells. Exosomes mediate the horizonal transfer of various macromolecules previously believed to be cell-autonomous in nature, including nonsecretory proteins, various classes of RNA, metabolites, and lipid membrane-associated factors. Exosomes derived from mesenchymal stem/stromal cells (MSCs) appear to be particularly beneficial for enhancing recovery in various models of disease. To date, there are over 200 preclinical studies of exosome-based therapies in a number of different animal models. Despite a growing number of studies reporting the therapeutic properties of MSC-derived exosomes, their underlying mechanism of action, pharmacokinetics, and scalable manufacturing remain largely outstanding questions. Here, we review the global trends associated with preclinical development of MSC-derived exosome-based therapies, including immunogenicity, source of exosomes, isolation methods, biodistribution, and disease categories tested to date. Although the in vivo data assessing the therapeutic properties of MSC-exosomes published to date are promising, several outstanding questions remain to be answered that warrant further preclinical investigation.",
keywords = "exosomes, extracellular vesicles, mesenchymal stem cells, mesenchymal stromal cells, microvesicles",
author = "Elahi, {Fanny M.} and Farwell, {D. Gregory} and Nolta, {Jan A.} and Anderson, {Johnathon D.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/stem.3061",
language = "English (US)",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "AlphaMed Press",

}

TY - JOUR

T1 - Preclinical translation of exosomes derived from mesenchymal stem/stromal cells

AU - Elahi, Fanny M.

AU - Farwell, D. Gregory

AU - Nolta, Jan A.

AU - Anderson, Johnathon D.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Exosomes are nanovesicles secreted by virtually all cells. Exosomes mediate the horizonal transfer of various macromolecules previously believed to be cell-autonomous in nature, including nonsecretory proteins, various classes of RNA, metabolites, and lipid membrane-associated factors. Exosomes derived from mesenchymal stem/stromal cells (MSCs) appear to be particularly beneficial for enhancing recovery in various models of disease. To date, there are over 200 preclinical studies of exosome-based therapies in a number of different animal models. Despite a growing number of studies reporting the therapeutic properties of MSC-derived exosomes, their underlying mechanism of action, pharmacokinetics, and scalable manufacturing remain largely outstanding questions. Here, we review the global trends associated with preclinical development of MSC-derived exosome-based therapies, including immunogenicity, source of exosomes, isolation methods, biodistribution, and disease categories tested to date. Although the in vivo data assessing the therapeutic properties of MSC-exosomes published to date are promising, several outstanding questions remain to be answered that warrant further preclinical investigation.

AB - Exosomes are nanovesicles secreted by virtually all cells. Exosomes mediate the horizonal transfer of various macromolecules previously believed to be cell-autonomous in nature, including nonsecretory proteins, various classes of RNA, metabolites, and lipid membrane-associated factors. Exosomes derived from mesenchymal stem/stromal cells (MSCs) appear to be particularly beneficial for enhancing recovery in various models of disease. To date, there are over 200 preclinical studies of exosome-based therapies in a number of different animal models. Despite a growing number of studies reporting the therapeutic properties of MSC-derived exosomes, their underlying mechanism of action, pharmacokinetics, and scalable manufacturing remain largely outstanding questions. Here, we review the global trends associated with preclinical development of MSC-derived exosome-based therapies, including immunogenicity, source of exosomes, isolation methods, biodistribution, and disease categories tested to date. Although the in vivo data assessing the therapeutic properties of MSC-exosomes published to date are promising, several outstanding questions remain to be answered that warrant further preclinical investigation.

KW - exosomes

KW - extracellular vesicles

KW - mesenchymal stem cells

KW - mesenchymal stromal cells

KW - microvesicles

UR - http://www.scopus.com/inward/record.url?scp=85073982977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073982977&partnerID=8YFLogxK

U2 - 10.1002/stem.3061

DO - 10.1002/stem.3061

M3 - Review article

C2 - 31381842

AN - SCOPUS:85073982977

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

ER -